What does this research mean for the field?

Baseline SUVmax on [18F]FDG-PET/CT and post-treatment Deauville and Lugano scores are effective prognostic markers for survival and early therapy failure in relapsed/refractory DLBCL patients undergoing CAR-T cell therapy. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The study aims to assess the prognostic potential of 18F FDG PET CT in patients with relapsed DLBCL undergoing CAR-T cell therapy.

June 1, 2025European Journal of Radiology OpenOpen Access

18FFDG-PET/CT in DLBCL-patients treated with CAR-T cell therapy: potential for defining patient prognosis

View Full Paper

Ask AI

Bookmark

Authors

HPH PetersDüsseldorf University Hospital BBBen‐Niklas BärmannDüsseldorf University Hospital ENEmil NovruzovDüsseldorf University Hospital

Discussion

Member takes

Implication

Randomized trial evaluates prognostic markers in DLBCL patients treated with CAR-T therapy, indicating potential early therapy failure.

Key Points

The study aims to assess the prognostic potential of 18F FDG PET CT in patients with relapsed DLBCL undergoing CAR-T cell therapy.
Retrospective analysis of 48 18F FDG PET CT scans from 18 DLBCL patients treated with CAR-T therapy.
Evaluated parameters include SUVmax, Deauville score, and Lugano classification over a follow-up period of 10 months.
Survival analyses for progression-free survival (PFS) and overall survival (OS) were conducted using Kaplan-Meier and Cox regression methods.
Patients with SUVmax > 9.0 at t0 had significantly shorter PFS (p = 0.04) and OS (p < 0.01).
Progressive disease at t1 (p = 0.02) and t2 (p < 0.01) correlated with reduced OS.
SUVmax > 9.0 at t0 (p = 0.03, HR=7.0, CI: 1.3–40.5) and Deauville score > 3 at t1 (p = 0.04, HR=8.2, CI: 1.1–61.3) indicated increased risk of progressive disease.

Cite This Study

Peters et al. (2025) studied this question.

synapsesocial.com/papers/6a20a15c6236d09b9bcd35d0 https://doi.org/10.1016/j.ejro.2025.100663

View Full Paper

Ask AI

Bookmark

18FFDG-PET/CT in DLBCL-patients treated with CAR-T cell therapy: potential for defining patient prognosis

Discussion

Member takes

Implication

Key Points

Cite This Study

18FFDG-PET/CT in DLBCL-patients treated with CAR-T cell therapy: potential for defining patient prognosis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider